Specifically, serous-like tumours have the worst prognosis and are characterized by a low immune infiltrate while POLE and MSI cancers are characterized by a high predicted neo-antigens load, overexpression of PD-1 and PD-L1, and massive CD3+ and CD8+ Tumour-associated lymphocytes infiltration, thus suggesting that these two subgroups might be the best candidates for immunotherapy (9–11). Here, CD8A is linked to neoplasm.